-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Trastuzumab Biosimilar in Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer (HER2+ Breast Cancer) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Trastuzumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Selatinib Ditosilate in Breast Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Selatinib Ditosilate in Breast Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Selatinib Ditosilate in Breast Cancer Drug Details: Selatinib ditosilate is under...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Eftozanermin Alfa in Diffuse Large B-Cell Lymphoma Drug Details:...
-
Product Insights
NewHospital Acquired Pneumonia (HAP) Clinical Trial Analysis by Phase, Trial Status, End Point, Sponsor Type and Region, 2024 Update
GlobalData's clinical trial report, “Hospital Acquired Pneumonia (HAP) - Global Clinical Trials Review, 2024" provides an overview of Hospital Acquired Pneumonia (HAP) Clinical trials scenario. This report provides top line data relating to the clinical trials on Hospital Acquired Pneumonia (HAP). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Vidutolimod in Basal Cell Carcinoma (Basal Cell Epithelioma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Vidutolimod in Basal Cell Carcinoma (Basal Cell Epithelioma) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Vidutolimod in Basal Cell Carcinoma (Basal Cell...
-
Sector Analysis
NewNew Drug Approvals and Their Contract Manufacture – 2024 Edition
This report is the 14th edition of our long-running analysis of the CMO industry, using the FDA's NDA approvals as the primary indicator of performance. New Drug Approvals and Their Contract Manufacture (formerly called "CMO Scorecard") is critical for benchmarking the performance of the contract manufacturing organization (CMO) industry and the relative performance of major CMOs. This year's edition includes a discussion of how inflation and increasing global conflict has impacted pharma manufacturers.
-
Product Insights
Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) – Drugs In Development, 2023
Global Markets Direct’s, ‘Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) - Drugs In Development, 2023’, provides an overview of the Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – QLS-31905 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QLS-31905 in Pancreatic Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QLS-31905 in Pancreatic Cancer Drug Details: QLS-31905 is under development for the...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – QLS-31905 in Gallbladder Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - QLS-31905 in Gallbladder Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. QLS-31905 in Gallbladder Cancer Drug Details: QLS-31905 is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Mibavademab in Acquired Generalized Lipodystrophy (Lawrence Syndrome) Drug...